Loading clinical trials...
Loading clinical trials...
The purpose of this study is to investigate the safety and tolerability of AZD5658 following ascending single oral doses in Type 2 Diabetics. It will also estimate the maximum tolerated dose.
Keep your clinical trial research organized — questions to ask, what to expect, and key details.
Lead Sponsor
AstraZeneca
NCT07187830 · Chronic Kidney Disease in Type 2 Diabetes, Obesity & Overweight
NCT06613854 · Type 2 Diabetes Mellitus (T2DM)
NCT07542834 · Type 2 Diabetes (T2DM), Geriatric Syndromes, and more
NCT07272837 · Type 2 Diabetes, Obesity, and more
NCT07232537 · Chronic Kidney Disease, Type 2 Diabetes Mellitus
Research Site
Chula Vista, California
Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.
Start free trial →Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions